Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Phase 2
Conditions
First Posted Date
2004-04-13
Last Posted Date
2014-01-06
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Registration Number
NCT00012311
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

First Posted Date
2004-04-12
Last Posted Date
2013-06-26
Lead Sponsor
Beth Israel Deaconess Medical Center
Registration Number
NCT00004082
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

First Posted Date
2004-04-08
Last Posted Date
2012-10-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
116
Registration Number
NCT00080678
Locations
🇺🇸

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2004-04-08
Last Posted Date
2018-04-24
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
12
Registration Number
NCT00080665
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

First Posted Date
2004-04-08
Last Posted Date
2019-03-21
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
19
Registration Number
NCT00080626
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Chemotherapy in Treating Patients With Solid Tumors

First Posted Date
2004-04-06
Last Posted Date
2013-07-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
57
Registration Number
NCT00003103
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus

Phase 2
Completed
Conditions
First Posted Date
2004-04-02
Last Posted Date
2023-06-15
Lead Sponsor
Eastern Cooperative Oncology Group
Registration Number
NCT00003864
Locations
🇺🇸

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

🇺🇸

Hahnemann University Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 71 locations

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
First Posted Date
2004-03-24
Last Posted Date
2007-06-08
Lead Sponsor
Point Therapeutics
Registration Number
NCT00080080
Locations
🇺🇸

New York Oncology/Hematology--Albany Regional Cancer Center, Albany, New York, United States

🇺🇸

Mary Crowley Medical Research Center, Dallas, Texas, United States

🇺🇸

Cancer Center of Florida, Ocoee, Florida, United States

and more 7 locations

Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2
Conditions
First Posted Date
2004-03-17
Last Posted Date
2013-12-19
Lead Sponsor
Amgen
Registration Number
NCT00006215
Locations
🇺🇸

Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, Memphis, Tennessee, United States

🇺🇸

Texas Cancer Care, Fort Worth, Texas, United States

🇺🇸

Gould Medical Group, Modesto, California, United States

and more 16 locations

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

First Posted Date
2004-03-16
Last Posted Date
2012-06-01
Lead Sponsor
Northwestern University
Registration Number
NCT00004913
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

🇺🇸

Indiana University Cancer Center, Indianapolis, Indiana, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath